Cyclacel Pharmaceuticals, Inc. (CYCCP)


Stock Price Forecast

May 20, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cyclacel Pharmaceuticals, Inc. chart...

About the Company

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

CEO

Spiro Rombotis

Exchange

NASDAQ

Website

http://www.cyclacel.com

$0M

Total Revenue

None

Employees

$M

Market Capitalization

None

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CYCCP News

CYCC Cyclacel Pharmaceuticals, Inc.

3d ago, source: Seeking Alpha

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s lead product includes ...

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

12d ago, source:

The R&D tax credit has been an important source of non-dilutive capital supporting Cyclacel’s programs. We appreciate this governmental support as we evaluate potential precision medicine approaches ...

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

28d ago, source: Business Insider

BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...

Cyclacel Pharmaceuticals, Inc. (CYCCP)

1mon ago, source: Yahoo Finance

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

12d ago, source: Nasdaq

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...

Cyclacel Pharmaceuticals Inc CYCC

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cyclacel Pharmaceuticals, Inc. (CYCC)

13d ago, source: Yahoo Finance

Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel ...

Cyclacel Pharmaceuticals Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cyclacel Pharmaceuticals Inc

20d ago, source: U.S. News & World Report

Not all exchange-traded funds are created equal. These five-star funds are some of the cream of the ETF crop. Investing can help you reach the $1 million mark if you start early, stay in the ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...